logo
Why giant moa — a bird that once towered over humans — are even harder to de-extinct than dire wolves

Why giant moa — a bird that once towered over humans — are even harder to de-extinct than dire wolves

Yahoo6 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A biotech company that claims to have brought dire wolves back from extinction has announced plans to resurrect giant extinct birds called moa. However, experts say that dire wolves were never truly resurrected, and that moa will be even harder to de-extinct.
Earlier this month, Texas-based Colossal Biosciences said it had teamed up with filmmaker Sir Peter Jackson and Indigenous partners to bring back the 12-foot-tall (3.6 meter) South Island giant moa (Dinornis robustus) and other moa species. These flightless birds roamed New Zealand until they were hunted to extinction by early Māori settlers around 600 years ago.
The new project will be coordinated by the Ngāi Tahu Research Centre, a joint venture between the main Māori tribe (iwi) on the South Island of New Zealand and the University of Canterbury in Christchurch. It's a multifaceted project that aims to combine traditional Māori knowledge, wildlife conservation and genetic engineering-driven de-extinction.
However, the project has already come under fire. Critics have highlighted that some Māori iwi oppose de-extinction, while several scientists have argued that genetically modifying living animals can't bring back lost species. The scientific criticism is similar to the commentary after Colossal unveiled its "dire wolves" — a species that went extinct more than 10,000 years ago.
Colossal's "dire wolves" are genetically modified gray wolves (Canis lupus) with 20 gene edits. The company claims they are dire wolves (Aenocyon dirus) because they have some observable traits identified in the dire wolf genome, such as increased size and a white coat. However, genetically, they're still mostly gray wolves. The same will be true for the living animal Colossal modifies for the moa project — but for moa, it's even more complicated.
Related: T. rex researchers eviscerate 'misleading' dinosaur leather announcement
Moa's closest living relatives are a group of South American birds called tinamous. The largest tinamou species is smaller than most domestic chickens, so is minuscule compared to South Island giant moa. Australia's emus (Dromaius novaehollandiae) are the next closest relative, but while these large flightless birds are physically more similar to giant moa, they're still not as big, growing to an average of 5.7 feet (1.75 m) tall. Both of these living relatives also separated from moa a long time ago.
"The common ancestor of the moa and tinamou lived 58 million years ago, while the common ancestor of moa and emu lived 65 million years ago," Nic Rawlence, director of the Otago Palaeogenetics Lab at the University of Otago in New Zealand and a critic of the moa plan, told Live Science in an email. "That's a lot of evolutionary time."
To put that in context, dire wolves only split from modern wolf-like canids — the group that includes gray wolves — around 5.7 million years ago (or even more recently at 4.5 million years ago, according to a recent preprint involving some of Colossal's scientists). That means moa had a lot more time to evolve unique traits.
Image 1 of 3
Image 2 of 3
Image 3 of 3
Rawlence explained that moa and their closest living relatives descended from a group of small flying birds called lithornids. These animals lived around the world and gave rise to different groups that independently lost the ability to fly. As Rawlence puts it, these flightless birds were "filling the job vacancies in the ecosystem left by the extinction of the dinosaurs."
Moa and emu lost flight through a process called convergent evolution, whereby different organisms evolve similar traits. That means, according to Rawlence, that the physiological and developmental mechanisms behind their body plans evolved independently, potentially via different genetic routes, which poses a challenge when it comes to bringing moa back.
"Genetically engineering specific genes in an emu to match a moa could have dire developmental consequences given this independent and convergent evolutionary history," Rawlence said.
Live Science asked Colossal whether there were any health risks associated with genetically engineering living animals to be more like extinct animals. Colossal's chief science officer, Beth Shapiro, told Live Science that the company was certified by the American Humane Society and that animal welfare was a priority in their work.
"We thoroughly evaluate health risks of any proposed edit before selecting them for our final list of edits," Shapiro said in an email.
Colossal's moa de-extinction plan
Before Colossal begins creating its modern-day moa, the company aims to sequence and rebuild the genomes of all nine extinct moa species, while also sequencing high-quality genomes of their closest living relatives. This will allow Colossal to identify the changes that led to the moa's unique traits, including their large body size and lack of wings, according to Colossal's website.
The researchers will then use primordial germ cells, the precursors of sperm or egg cells, from living species to "build a surrogate bird" and make genetic changes to create birds with moa traits. The company needs both male and female surrogates to carry the sperm and egg of their "moa," to then produce the genetically modified offspring.
Colossal's website states that emus' larger size makes them a more suitable surrogate than tinamous. However, details on this part of the process are limited. Shapiro told Live Science that they were "still in the process of selecting the surrogate species for moa de-extinction."
Emus lay large green eggs, around 5 inches (12 cm) long and 3.5 inches (9 cm) wide. Still, that's nothing compared to a South Island giant moa egg, which were 9.5 inches (24 cm) by 7 inches (17.8 cm).
RELATED STORIES
—'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice'
—Colossal's de-extinction campaign is built on a semantic house of cards with shoddy foundations — and the consequences are dire
—Dodos were fast and powerful, not slow and inept, definitive preserved specimen suggests
"A South Island giant moa egg will not fit inside an emu surrogate, so Colossal will have to develop artificial surrogate egg technology," Rawlence said.
Colossal briefly mentioned artificial eggs during its moa announcement, but didn't provide details on this part of the process. Live Science asked Colossal whether they could explain how Colossal will hatch a South Island giant moa.
"Our exogenous development team is exploring different strategies for artificial egg incubation, which will have application both for moa de-extinction and bird conservation work," Shapiro said in an email.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU pharma chief calls for European Nasdaq to boost biotech innovation
EU pharma chief calls for European Nasdaq to boost biotech innovation

Yahoo

time13 hours ago

  • Yahoo

EU pharma chief calls for European Nasdaq to boost biotech innovation

Stefan Oelrich, president of Bayer's pharmaceutical division and newly appointed head of the EU's pharmaceutical lobby EFPIA, pointed out the urgent need for capital market reform to support biotech development in Europe. 'We need the equivalent of a Nasdaq in Europe where we can raise capital for biotech. Because biotech is not just about government finance,' Oelrich said during a press conference last week. Launched in 1971, the Nasdaq (originally the National Association of Securities Dealers Automated Quotations) was the world's first electronic stock market. Known for its fully electronic trading model, the exchange has historically been attractive to fast-growing sectors, including life science, listing some of the world's largest tech companies, including Apple, Microsoft, and Google. Oelrich argued that Europe must urgently develop a similar equity-driven financing ecosystem. 'Today, there is very limited venture capital available, which is largely due to the way we manage equities. We invest our equities not in venture, but elsewhere,' he said. According to him, the lack of early-stage capital means European biotech innovations often migrate elsewhere — especially to the US, where funding and commercialisation opportunities are more robust. 'The transition from basic research to patented applications tends to follow where the capital is. We must ensure that innovation generated in European universities and research institutions stays in Europe,' he warned. 'Why don't we do it?' His remarks came just ahead of the unveiling of the EU's long-awaited Life Sciences Strategy, which aims to revive Europe's position as a hub for biotech research and development. The strategy acknowledges that the gap in venture capital investment is widening in Europe. It points to the continent's fragmented capital markets and heavy reliance on bank loans, which are often limited in volume and duration, as major structural issues. The strategy also recommends strengthening innovation hubs and integrating them into value chains to better attract private investment. However, it does not place significant emphasis on completing the EU's Capital Markets Union (CMU), a key demand from Oelrich. 'This may sound ambitious, but it's absolutely doable. Interestingly, everyone I talk to recognises the need: So why aren't we acting on it?' Oelrich asked. He also suggested that part of Europe's pension and life insurance capital could be redirected toward venture investment if appropriate political frameworks were put in place. 'Inventions can find a market here as it's not only about a lack of capital in Europe: It's about how we allocate it. We need to do a better job,' he concluded. The broader context The EU's Capital Markets Union remains incomplete, with progress hindered by regulatory divergence, inconsistent enforcement, and political resistance to deeper integration. While the CMU does not directly aim to create new stock exchanges, it does support efforts to expand access to capital, particularly for small and medium-sized enterprises (SMEs). This improved access could encourage the development of specialised or regional exchanges, though the broader goal remains integration rather than fragmentation. Currently, Europe lacks sector-specific stock exchanges. Major platforms like Euronext, the London Stock Exchange, Deutsche Börse, Nasdaq Nordic, and SIX Swiss Exchange list companies across a wide range of industries. Instead of dedicated exchanges, sector-focused investment is facilitated through indices such as the STOXX Europe 600 family, which tracks sectors like banking, automotive, and leisure. Still, for many in the biotech sector, the absence of a specialised capital-raising platform remains a barrier. Whether the EU will — and can — move to address this remains to be seen. Sign in to access your portfolio

RFK Jr. Turns to Fringe Medical Journal to Find New Hires
RFK Jr. Turns to Fringe Medical Journal to Find New Hires

Bloomberg

timea day ago

  • Bloomberg

RFK Jr. Turns to Fringe Medical Journal to Find New Hires

George Tidmarsh is a millionaire co-founder of a biotech firm, serial entrepreneur, neonatologist and adjunct professor at Stanford University. But his part in creating a fringe medical journal is the role that stands out as he takes a top post at the US Food and Drug Administration. Tidmarsh, who will lead the Center for Drug Evaluation and Research, is at least the fifth person appointed to a federal health agency under the helm of Robert F. Kennedy Jr. this year connected to the Journal of the Academy of Public Health.

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Yahoo

time2 days ago

  • Yahoo

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032. San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032. This extraordinary growth is propelled by the increasing adoption of bispecific antibody therapies in oncology and immunology, groundbreaking clinical outcomes, and robust R&D investments aimed at next-generation biologics. Bispecific antibodies are bioengineered molecules designed to simultaneously recognize and bind to two different antigens or epitopes. Unlike monoclonal antibodies that target a single antigen, bispecific antibodies can link a disease-related antigen (such as one found on cancer cells) to another molecule—often a T-cell—thus redirecting immune cells to attack malignant tissues with heightened precision. This dual-binding capability is unlocking new therapeutic possibilities in cancer, autoimmune diseases, and infectious diseases. As of 2024, over 300 bispecific antibodies are in global clinical development, with 14 already approved by the U.S. FDA, reflecting the sector's rapid growth and clinical validation. Download Free Sample Report PDF @ Global Bispecific Antibodies Market Key Players- Detailed Competitive Insights Amgen Genentech Akeso, Inc. Taisho Pharmaceutical Janssen Immunocore Adimab, Innovent Biologics, Inc. AstraZeneca Affimed GmbH Xencor F. Hoffmann-La Roche Ltd. Sanofi Regeneron Pharmaceuticals Inc. Pieris Pharmaceuticals, Inc. Eli Lilly Mereo BioPharma Group plc Merus MacroGenics, Inc. Sobi, TG Therapeutics Inc. Genmab A/S Alteogen Emergent BioSolutions Inc. Novartis AG Astellas Pharma Inc. Celgene Corporation Others Market Drivers 1. Increasing Cancer Prevalence Globally Cancer remains a global health crisis, with the World Health Organization (WHO) estimating around 19.3 million new cancer cases and nearly 10 million deaths in 2023 alone. Traditional therapies are often limited by poor specificity and severe side effects, which have shifted the focus toward more targeted modalities, such as bispecific antibodies. Their unique mechanism allows precise tumor targeting while preserving healthy tissues, making them a preferred choice for next-gen cancer therapies. 2. Regulatory Approvals and Accelerated Development Pathways The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have actively supported innovative antibody therapeutics. Between 2022 and 2024, the FDA approved six bispecific antibodies, a testament to their growing clinical value. Regulatory agencies are also introducing expedited pathways for breakthrough therapies, speeding up market entry for promising candidates. 3. Rising Investments in Immunotherapy and Biologics Governments and private players are significantly boosting funding for immunotherapy research. For instance, the U.S. National Cancer Institute (NCI) allocated over USD 15 billion toward cancer research in 2023, a portion of which is directed toward the development of targeted therapies, including bispecific antibodies. This capital influx is catalyzing clinical trials, molecule discovery, and scalable manufacturing solutions. Market Challenges Despite the optimistic trajectory, the bispecific antibodies market faces notable challenges: Complex Manufacturing: Producing bispecific antibodies involves intricate processes, such as protein folding and stability optimization, which increase production time and cost. High Development Costs: The R&D cycle for bispecific therapies is long and resource-intensive, often requiring large-scale trials and advanced biotechnological platforms. Immunogenicity Risks: Some bispecific formats can trigger unwanted immune responses, complicating their clinical profiles. Nonetheless, advances in antibody engineering, such as the development of Fc-engineered antibodies and T-cell engaging bispecifics (BiTEs), are helping overcome these limitations. Regional Insights North America is poised to maintain a dominant position in the global bispecific antibodies market. Its leadership is driven by: A well-established biotech and pharma industry. Substantial government and private R&D investments. Early and streamlined regulatory approvals. In 2023 alone, the U.S. government dedicated nearly USD 7.9 billion toward cancer research, a portion of which supports novel antibody-based treatments. Moreover, the presence of major biopharmaceutical companies and academic research centers ensures rapid clinical development. Asia-Pacific, on the other hand, is anticipated to experience the fastest growth rate. Countries such as China, India, and South Korea are: Increasing healthcare expenditures. Encouraging local biotech innovation. Expanding access to clinical trials and biologic therapies. China, for example, is investing heavily in biologics manufacturing capabilities and has introduced supportive regulations for fast-track drug approval, which will likely make the region a future hub for bispecific antibody development. TABLE OF CONTENT 1. Bispecific Antibodies Market Overview 1.1. Study Scope 1.2. Market Estimation Years 2. Executive Summary 2.1. Market Snippet 2.1.1. Bispecific Antibodies Market Snippet by Drug Type 2.1.2. Bispecific Antibodies Market Snippet by Indication 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel 2.1.4. Bispecific Antibodies Market Snippet by Country 2.1.5. Bispecific Antibodies Market Snippet by Region 2.2. Competitive Insights 3. Bispecific Antibodies Key Market Trends 3.1. Bispecific Antibodies Market Drivers 3.1.1. Impact Analysis of Market Drivers 3.2. Bispecific Antibodies Market Restraints 3.2.1. Impact Analysis of Market Restraints 3.3. Bispecific Antibodies Market Opportunities 3.4. Bispecific Antibodies Market Future Trends…… Get a detailed analysis on regions, market segments, customer landscape, and companies@ Market Segmentation by Indication The bispecific antibodies market is segmented by application into: Cancer Autoimmune and Inflammatory Disorders Others Among these, the oncology segment is forecasted to command the largest share throughout the forecast period. As of March 2025, over 650 bispecific antibodies are in clinical development globally—nearly all focused on oncology applications, and nine of the 11 bispecifics approved since 2021 target cancer, representing over 80% of recent regulatory approvals. Competitive Landscape & Innovation Strategies The bispecific antibody space is rapidly evolving with heightened competition among biotech giants and emerging players. Leading companies are prioritizing: Next-generation platforms for greater safety, flexibility, and efficacy. Strategic collaborations and licensing deals to expand pipeline access. Geographic expansion into emerging economies with rising healthcare demands. Biotech firms are utilizing AI-driven drug discovery, cell-line optimization, and novel bispecific formats (like dual-variable domain antibodies and knob-into-hole technologies) to advance their products. Some players are also entering into co-development agreements to reduce costs and accelerate regulatory milestones. Future Outlook The bispecific antibodies market is positioned at the forefront of immunotherapeutic innovation. With strong clinical potential, increasing funding, and a favorable regulatory climate, the sector is expected to witness substantial growth through 2032. As manufacturing bottlenecks are resolved and newer formats with improved safety emerge, bispecific antibodies will likely become standard components of combination therapies in oncology and immune-related disorders. In conclusion, the bispecific antibodies market offers immense opportunities for stakeholders across biotechnology, healthcare, and investment sectors. Its rapid evolution signals a paradigm shift in how complex diseases are treated, ushering in a new era of precision medicine. Browse more Reports from AnalystView Market Insights:CONTACT: U.S. Office: 11923 NE Sumner St STE 750924 Portland, Oregon, 97220, USA Phone: +1 615-326-5253 (U.S. Toll Free) Email: mayank@ Email: inquiry@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store